SciSparc (NASDAQ: SPRC) announced that NeuroThera Labs, a subsidiary in which it holds an approximately 75% controlling stake, has progressed its collaboration with Clearmind Medicine (NASDAQ:CMND) following the publication of an international patent application under the Patent Cooperation Treaty.
The patent relates to a new combination therapy designed to target weight loss and metabolic dysfunction-associated steatotic liver disease (MASLD).
According to the companies, the patent publication outlines the potential of a treatment combining 5-methoxy-2-aminoindane (MEAI) and Palmitoylethanolamide (PEA). The therapy is being explored as a non-hallucinogenic neuroplastogen approach aimed at addressing two major global health conditions: obesity and MASLD.
Obesity currently affects more than 890 million adults worldwide, while MASLD impacts roughly 30% of the global adult population.
Based on the expected mechanism of action, the companies believe the therapy could provide a safer, more accessible and potentially lower-cost alternative to GLP-1 agonist treatments currently used for obesity and related metabolic conditions.
By integrating Clearmind’s MEAI technology platform with NeuroThera’s PEA compound, the partners aim to respond to growing demand for treatments that are both effective and well tolerated in addressing obesity and liver health disorders.